BlackRock Fund Advisors’s Pacira BioSciences PCRX Stock Holding History

BlackRock Fund Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$62.1M	Buy	1,921,554 +239,173	+14%	+$7.98M	0.01%	1541
2016 Q3	$57.6M	Buy	1,682,381 +90,693	+6%	+$3.55M	0.01%	1481
2016 Q2	$53.7M	Buy	1,591,688 +9,454	+0.6%	+$465K	0.01%	1441
2016 Q1	$83.8M	Buy	1,582,234 +18,120	+1%	+$1.06M	0.02%	1102
2015 Q4	$120M	Sell	1,564,114 -94,879	-6%	-$5.37M	0.03%	813
2015 Q3	$68.2M	Buy	1,658,993 +29,805	+2%	+$1.83M	0.02%	1218
2015 Q2	$115M	Buy	1,629,188 +20,337	+1%	+$1.6M	0.03%	869
2015 Q1	$143M	Buy	1,608,851 +83,449	+5%	+$8.47M	0.03%	706
2014 Q4	$135M	Buy	1,525,402 +145,926	+11%	+$13.8M	0.03%	702
2014 Q3	$134M	Buy	1,379,476 +24,952	+2%	+$2.43M	0.04%	634
2014 Q2	$124M	Buy	1,354,524 +117,888	+10%	+$8.98M	0.04%	715
2014 Q1	$86.6M	Buy	1,236,636 +30,179	+3%	+$2.05M	0.03%	967
2013 Q4	$69.4M	Buy	1,206,457 +3,235	+0.3%	+$170K	0.02%	1149
2013 Q3	$57.8M	Buy	1,203,222 +142,024	+13%	+$5.18M	0.02%	1213
2013 Q2	$30.8M	Buy	+1,061,198	New	+$30.7M	0.01%	1539

Other funds holding PCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock Fund Advisors's PCRX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Pacira BioSciences (PCRX) stake by 14% in Q4 2016, buying an estimated $7.98M and bringing the position to 1,921,554 shares worth $62.1M. The position accounts for 0.01% of the portfolio, ranked #1541.

BlackRock Fund Advisors first reported a position in PCRX in Q2 2013 and has held it in 15 quarters since. The position peaked at $143M in Q1 2015. 182 funds tracked by Wall St. Rank hold PCRX as of Q4 2016.

BlackRock Fund Advisors held 1,921,554 shares of Pacira BioSciences worth $62.1M as of Q4 2016.
BlackRock Fund Advisors bought 239,173 Pacira BioSciences shares in Q4 2016, an estimated $7.98M.
Pacira BioSciences made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1541 holding.
BlackRock Fund Advisors first reported a position in Pacira BioSciences in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Pacira BioSciences position peaked at $143M in Q1 2015.
182 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.